Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 06, 2024

BUY
$3.6 - $5.79 $360 - $579
100 New
100 $0
Q3 2023

Nov 03, 2023

SELL
$3.14 - $11.2 $395 - $1,411
-126 Reduced 4.98%
2,402 $9,000
Q2 2023

Aug 09, 2023

BUY
$8.45 - $12.48 $18,860 - $27,855
2,232 Added 754.05%
2,528 $25,000
Q1 2023

May 09, 2023

BUY
$9.21 - $14.98 $257 - $419
28 Added 10.45%
296 $3,000
Q4 2022

Feb 13, 2023

SELL
$8.57 - $17.0 $719 - $1,428
-84 Reduced 23.86%
268 $2,000
Q3 2022

Oct 27, 2022

SELL
$12.56 - $17.54 $3,994 - $5,577
-318 Reduced 47.46%
352 $5,000
Q2 2022

Aug 01, 2022

BUY
$10.55 - $18.81 $1,624 - $2,896
154 Added 29.84%
670 $9,000
Q1 2022

May 11, 2022

BUY
$11.67 - $26.72 $1,178 - $2,698
101 Added 24.34%
516 $9,000
Q4 2021

Feb 11, 2022

BUY
$13.77 - $42.56 $5,714 - $17,662
415 New
415 $11,000

Others Institutions Holding TSVT

About 2seventy bio, Inc.


  • Ticker TSVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,873,600
  • Market Cap $115M
  • Description
  • 2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a col...
More about TSVT
Track This Portfolio

Track Us Bancorp \De\ Portfolio

Follow Us Bancorp \De\ and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.